(Q34978486)

English

Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.

scientific article

Statements

Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. (English)
27 October 2014

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit